CN110547975B - Cosmetic material composition containing epipinoresinol - Google Patents
Cosmetic material composition containing epipinoresinol Download PDFInfo
- Publication number
- CN110547975B CN110547975B CN201910455174.XA CN201910455174A CN110547975B CN 110547975 B CN110547975 B CN 110547975B CN 201910455174 A CN201910455174 A CN 201910455174A CN 110547975 B CN110547975 B CN 110547975B
- Authority
- CN
- China
- Prior art keywords
- epipinoresinol
- skin
- composition
- present
- cosmetic material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to a cosmetic material composition for preventing skin aging, which contains epipinoresinol as an active ingredient, and a skin external agent composition for improving dermatitis. The composition of the present invention improves wrinkles caused by skin aging by inhibiting MMP-1 and promoting the production of type I procollagen, and exhibits anti-inflammatory effects by inhibiting IL-6 to inhibit inflammatory reaction.
Description
Technical Field
The present invention relates to a Cosmetic Composition (Cosmetic Composition) comprising epipinoresinol.
Background
Skin aging is affected by genetics, environmental exposure (UV irradiation, mechanical shock), hormonal changes, metabolic processes (reactive oxygen species, sugars, aldehydes, and other highly reactive compounds). These factors lead to cumulative changes in the structure, function, and appearance of the skin. Human skin aging is roughly divided into: intrinsic aging that develops with biological processes and over time; and external aging (photoaging) caused by environmental conditions such as continuous light, stress, smoking, etc. Clinically, intrinsically aged skin is characterized by being thin, dry, pale, loss of elasticity, having many fine wrinkles, and in the case of aged skin caused by external environment, deep wrinkles, blotchy, rough skin, and the like appear, having a greater effect on the skin. Although aged skin and photoaged skin differ morphologically and histologically with clear distinction in appearance, recent studies have shown that both types of aging have important molecular characteristics including collagen degradation, reduction in procollagen synthesis, damage to connective tissue, and the like, including signaling pathways. In addition, environmental effects such as UV irradiation can accelerate important aspects of intrinsic aging.
From a histological point of view, skin aging is manifested by a change in the composition of Extracellular matrix proteins (Extracellular matrix proteins) that form the matrix in the dermis of the skin. Collagen in the dermal extracellular tissue gives strength and tension to the skin, thereby protecting the skin from external stimuli or force, and collagen accounts for 90% of the dermal layer, so that the reduction of collagen is closely associated with skin aging and wrinkle formation. The major cross-linked components of healthy dermis are type I collagen and type III collagen. Collagen is produced primarily in fibroblasts in the dermis layer, and the rate of proliferation of aged skin cells is reported to be reduced compared to young skin cells. This results in changes in the composition and content of the dermal matrix constituents, thereby accelerating aging. Furthermore, in skin damaged by photoaging, the precursors of both collagens are significantly reduced, and their reduction is associated with clinical severity. Degradation of collagen degrades with age, but when exposed to stimuli such as ultraviolet rays, the biosynthesis of collagenases (MMPs) increases, the synthesis of collagen decreases, and wrinkles are formed. Collagenase (MMPs) is a zinc-dependent intracellular protease that degrades or reconstitutes components of the dermal extracellular structure, where MMP-1 acts on and segments dermal collagen. Therefore, regulation of the amount and activity of the enzyme synthesis plays an important role in wrinkle formation.
Retinol (Retinol) and derivatives named as retinoids are the most representative substances as skin aging-ameliorating substances, and these substances are known to have excellent effects in various aspects such as psoriasis, aging, cancer, and acne. In addition, it is known that collagenase (MMP-1) is inhibited to prevent loss of collagen when retinoid is applied to the skin, stimulates formation of collagen, thereby preventing endogenous aging and photoaging and restoring the skin. However, despite these effects, when applied to the skin, local skin irritation such as erythema, pruritus, psoriasis, desquamation, etc. is caused. Therefore, there is a need to develop a new wrinkle-improving substance that is safe to the living body and has better collagenase (MMP-1) inhibition and collagen synthesis ability than the existing substances.
Documents of the prior art
Patent document
Patent document 1: KR 10-2013-0066581
Disclosure of Invention
The present inventors have made studies to develop a cosmetic composition containing a component which improves the skin aging phenomenon and does not cause skin irritation, and as a result, have developed a composition containing, as an active ingredient, epipinoresinol having anti-aging, wrinkle-improving, and anti-inflammatory effects.
Accordingly, an object of the present invention is to provide a composition comprising epipinoresinol as an active ingredient.
However, the technical problems to be solved by the present invention are not limited to the above-mentioned problems, and other problems not mentioned can be clearly understood by those skilled in the art from the following description.
In order to achieve the above object of the present invention, the present invention provides a cosmetic composition for preventing skin aging, which comprises epipinoresinol as an active ingredient.
An embodiment of the present invention is characterized in that the composition improves skin wrinkles.
A further embodiment of the present invention is characterized in that the epipinoresinol is contained in an amount of 0.001 to 30% by weight relative to the total weight of the composition.
Another embodiment of the present invention is characterized in that said epipinoresinol inhibits the expression of MMP-1 and IL-6 and promotes the production of type I procollagen.
A further embodiment of the invention is characterized in that the composition is in the form of one or more formulations selected from the group consisting of skin lotions, emulsions and creams.
In addition, the present invention provides a composition for external application to skin for ameliorating dermatitis, the composition comprising epipinoresinol as an active ingredient.
An embodiment of the present invention is characterized in that the dermatitis is one or more selected from the group consisting of atopic dermatitis, allergic dermatitis, eczema, contact dermatitis, erythema, and psoriasis.
A further embodiment of the present invention is characterized in that the epipinoresinol is contained in an amount of 0.001 to 30% by weight relative to the total weight of the composition.
Another embodiment of the present invention is characterized in that said epipinoresinol inhibits the expression of MMP-1 and IL-6 and promotes the production of type I procollagen.
Another embodiment of the present invention is characterized in that the skin external agent composition improves red swelling, edema, chancroid or pain caused by dermatitis.
Another embodiment of the present invention is characterized in that the composition for external application to skin has one or more dosage forms selected from the group consisting of a Lotion (tonic), a skin cleansing Lotion (Lotion), an emulsion, a cream, an ointment, a gel, a spray, a mousse, a liquid preparation, a mask, and a patch.
Effects of the invention
The cosmetic material composition and the pharmaceutical composition of the present invention have little skin irritation and excellent skin stability, and have functions of promoting collagen biosynthesis and recovering damaged cells. In addition, the production of collagenase promotes the biosynthesis of collagen, thereby exhibiting effects of preventing skin aging, regenerating skin, and relieving irritation.
Drawings
FIG. 1 is a graph showing the results of confirming MMP-1 inhibitory activity of epipinoresinol.
FIG. 2 is a graph showing the results of confirming the IL-6 inhibitory activity of epipinoresinol.
Fig. 3 is a graph showing the results of confirming the procollagen production-promoting effect of epipinoresinol.
Detailed Description
In order to solve the problems of the prior art that the existing skin aging improving substances cause skin irritation reactions, the invention pays attention to the physiological activity function of the epipinoresinol in the process of searching for substances which have small irritation to the skin and can prevent and improve the skin aging. Then, as a result of confirming the physiological activity of epipinoresinol, it was confirmed that the matrix metalloproteinase-1 (MMP-1) gene and interleukin-6 (IL-6) activity were inhibited and the procollagen production was promoted, and it was confirmed that epipinoresinol can be suitably used in cosmetic compositions for preventing aging and skin external preparations.
Accordingly, it is an object of the present invention to provide a cosmetic composition for preventing skin aging, which comprises epipinoresinol.
The cosmetic composition has the effects of preventing the formation of wrinkles on the skin, improving the wrinkles that have already formed, and thus, preventing skin aging. Thus, the cosmetic material composition is effective in improving skin aging caused by exogenous factors or endogenous factors. The exogenous factors refer to various external factors, for example, ultraviolet rays, and the endogenous factors are also referred to as time factors, mainly factors caused by the lapse of time.
Specifically, the cosmetic material composition of the present invention containing epipinoresinol has the effects of promoting the production of collagen, and restoring damaged cells due to the promotion of cell proliferation.
In addition, by reducing collagenase, wrinkle-improving effect and anti-aging effect can be exhibited. That is, when the cosmetic composition of the present invention is treated, the expression level of matrix metalloproteinase-1 (MMP-1) gene, which accelerates wrinkle formation by collagen degradation, can be reduced.
In addition, interleukin-6 (IL-6), which is an inflammatory cytokine, is known to affect the expression of MMP due to ultraviolet rays. Therefore, the present inventors also confirmed that the expression of IL-6 is reduced when the cosmetic material composition of the present invention is treated.
In particular, epipinoresinol of the present invention may be used by separating from forsythia suspense, Holly Osmanthus, eucommia ulmoides, etc., or may be used by purchasing commercially available epipinoresinol. When the epipinoresinol is isolated from the forsythia suspense, Holly Osmanthus and eucommia ulmoides, water, ethanol, methanol, acetone, butanol extracts or mixed solvents thereof are used, water or ethanol extracts are preferably used, and ethanol extracts are more preferably used. The extraction method can be freely selected from methods known to those skilled in the art.
In the cosmetic composition of the present invention, the content of the epipinoresinol may be 0.001 to 30% by weight, preferably 0.01 to 15% by weight, relative to the total weight of the cosmetic composition. When the content is less than 0.001% by weight, the skin-improving effect is hardly obtained, and when the content is more than 30% by weight, the formulation is difficult and the feeling in use is reduced.
In addition, the formulation of the cosmetic material composition may be a toner, an emulsion or a cream. The composition can be in the form of a skin lotion, skin softener, toner, astringent, lotion, milk lotion, moisturizing lotion, nourishing lotion, massage cream, nourishing cream, moisturizing cream, hand cream, foundation lotion, essence, nourishing essence, facial mask, soap, foaming cleanser, face cream, body lotion, or body wash.
Further, the effect of reducing inflammation by the above-mentioned epipinoresinol was confirmed from the effect of reducing the expression of IL-6, and therefore, the composition can also be used as a composition for external skin preparations for dermatitis improvement containing epipinoresinol as an active ingredient.
The dermatitis may be atopic dermatitis, allergic dermatitis, eczema, and contact dermatitis.
In addition, the composition can improve red swelling, edema, chancroid or pain caused by dermatitis, and improve local skin irritation such as erythema, pruritus, psoriasis, desquamation, etc.
The skin external preparation composition comprising epipinoresinol of the present invention may further include suitable carriers, excipients and diluents, which are generally used for preparing skin external preparation compositions.
The topical skin composition containing epipinoresinol of the present invention may be formulated into lotions (tonics), skin cleansers (lotons), lotions, creams, ointments, gels, sprays, mousses, liquid preparations, masks, or patches, respectively, according to a conventional method, and used. The carrier, excipient and diluent included in the composition comprising epipinoresinol may be lactose (lactose), dextrose (dextrose), sucrose (sucrose), oligosaccharide (oligosaccharide), sorbitol (sorbitol), mannitol (manitol), xylitol (xylitol), erythritol (erythritol), maltitol (maltitol), starch (starch), acacia gum (acacia rubber), alginate (alginate), gelatin (gelatin), Calcium phosphate (Calcium phosphate), Calcium silicate (Calcium silicate), cellulose (cellulose), methylcellulose (methylcellulose), microcrystalline cellulose (microcrystalline cellulose), polyvinylpyrrolidone (polyvinylpyrrolidone), water, methyl hydroxybenzoate (hydroxymethyl benzoate), propyl hydroxybenzoate (propylbenzoate), magnesium stearate (talc), mineral oil (magnesium stearate), mineral oil (mineral oil).
The preferred application amount of the composition of the present invention varies depending on the condition and body weight of the patient, the extent of the disease, the form of the drug, the route and period of administration, but can be appropriately selected by those skilled in the art. For the desired effect, the composition of the present invention is administered at 0.0001 to 100mg/kg per day, preferably 0.001 to 10mg/kg per day. The administration may be once daily or divided into several doses per day. The amount administered is not intended to limit the scope of the invention in any way.
The present invention may further comprise conventional adjuvants and carriers commonly used in antioxidants, stabilizers, solubilizers, vitamins, pigments, perfumes, etc. For example, the cosmetic material composition may further include auxiliary ingredients such as glycerin, butylene glycol, polyoxyethylene hydrogenated castor oil, tocopherol Acetate (tocophenyl Acetate), citric acid (citric acid), Panthenol (Panthenol), squalane (squalane), sodium citrate (sodium citrate), allantoin (allintoin), and may include solvents such as hexylene glycol (Hexanediol), purified water, and the like.
The cosmetic material composition of the present invention can be prepared in any dosage form conventionally produced in the art. Specifically, the cosmetic material composition may be one or more dosage forms selected from the group consisting of skin lotion, skin softener, skin toner, astringent, milky lotion, moisturizing lotion, nourishing lotion, massage cream, nourishing cream, moisturizing cream, hand cream, foundation lotion, essence, nourishing essence, gel, mask, soap, foaming cleanser, face cream, body lotion, body essential oil, and body wash.
For example, when the dosage form of the present invention is an ointment, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth (tragacanth), cellulose derivatives, polyethylene glycol, colloidal silica (silica), bentonite (bentonite), silica (silica), talc, zinc oxide (zinc oxide), and the like may be contained as a carrier ingredient.
As another example, when the dosage form of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide (aluminum hydroxide), Calcium Silicate (Calcium Silicate), polyamide powder (polyamide powder), or the like may be contained as a carrier component, and particularly, when the dosage form of the present invention is a spray, a propellant such as Chlorofluorohydrocarbon (Chlorofluorohydrocarbon), Propane/butane (Propane/butane), dimethyl ether (dimethyl ether), or the like may be contained.
As another example, when the formulation of the present invention is a solution or emulsion, a solvent, a solubilizer, an emulsifier, and the like may be included as a carrier component, and specifically, water, ethanol, Isopropanol (isopropyl alcohol), Ethyl carbonate (Ethyl carbonate), Ethyl acetate (Ethyl acetate), benzyl alcohol (benzyl alcohol), benzyl benzoate (benzyl benzoate), propylene glycol, 1, 3-butylene glycol oil (1,3-butyl glycol oil), glycerol fatty acid ester (glycerol aliphatic ester), polyethylene glycol, fatty acid ester of sorbitan, and the like may be included.
In addition, when the dosage form of the present invention is a suspension, a liquid phase diluent such as water, ethanol, propylene glycol, or the like; suspending agents such as Ethoxylated isostearyl alcohol (Ethoxylated isostearyl alcohol), Polyoxyethylene sorbitol ester (polyoxyyethylene sorbent ester), and Polyoxyethylene sorbitan ester (polyoxyyethylene sorbent ester); microcrystalline cellulose, Aluminum metahydroxide (Aluminum metahydroxide), bentonite, agar, tragacanth, and the like.
When the formulation of the present invention is a surfactant-containing detergent, Fatty alcohol sulfates (Aliphatic alcohols sulfates), Fatty alcohol ether sulfates (Aliphatic alcohol ether sulfates), sulfosuccinic acid monoesters (sulfosuccinic acid monoesters), isethionates (isethionates), imidazoline derivatives (imidazolium derivitives), methyl taurates (methyltaurates), sarcosinates (sarcosinates), Fatty acid amide ether sulfates (Fatty acid amide ether sulfates), alkylamido betaines (alkylamidobetaines), Fatty alcohols, Fatty acid glycerides, Fatty acid diethanolamides (Fatty acid diethanolamides), vegetable oils, lanolin derivatives, ethoxylated glycerol Fatty acid esters (ethoxylated glycerol Fatty acid esters), and the like may be included as a carrier component.
More specifically, when the formulation of the present invention is a skin-refreshing aqueous solution, it may further include one or more selected from the group consisting of glycerin, butylene glycol, polyoxyethylene (60) hydrogenated castor oil, polysorbate 80, ethanol, a preservative, a perfume, and purified water.
In addition, when the formulation of the present invention is an emulsion, it may further include one or more selected from the group consisting of glycerin, butylene glycol, glyceryl stearate/PEG-100 stearate, polysorbate 60, sorbitan sesquioleate, squalane, caprylic/capric triglyceride, shea butter, stearyl alcohol, stearic acid, carboxyvinyl polymer, arginine, preservative, perfume, and purified water.
In addition, when the formulation of the present invention is a cream, it may further include one or more selected from the group consisting of glycerin, butylene glycol, glyceryl stearate/PEG-100 stearate, polysorbate 60, sorbitol stearate, vegetable squalane, jojoba oil, caprylic/capric triglyceride, aloe vera, beeswax, stearyl alcohol, behenyl alcohol, stearic acid, carboxyvinyl polymer, arginine, polydimethylsiloxane, preservative, perfume, and purified water.
Another aspect of the present invention provides a functional cosmetic for preventing skin aging, regenerating and relieving irritation, which comprises the above cosmetic material composition.
Another aspect of the present invention provides a quasi-drug composition for preventing skin aging, regenerating and relieving irritation, which comprises epipinoresinol as an effective ingredient. In the present invention, the term "quasi-drug" means: fibers, rubber articles or articles similar thereto for use in the treatment, alleviation, treatment or prevention of diseases in humans or animals; the effect on human body is weak or not directly acting on human body, and is not an article of appliances or machines and the like; articles that are not instruments, machines or devices among articles used for the purpose of diagnosis, treatment, alleviation, treatment or prevention of diseases in humans or animals as one of preparations used for sterilization, disinfestation and similar uses for the prevention of infectious diseases; and articles that are not appliances, machines or devices, among articles used for the purpose of exerting pharmacological effects on the structure and function of humans or animals.
When the composition of the present invention is used as a quasi-drug additive, the above-mentioned composition may be added directly or used together with other quasi-drugs or quasi-drug ingredients, and may be used as appropriate according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined depending on the intended use.
In addition, in the quasi-drug composition, the apparent pinoresinol content is 0.001 to 30% by weight, preferably 0.01 to 15% by weight, relative to the total weight of the quasi-drug composition. When the content is less than 0.001 wt%, the effect of improving wrinkles is difficult to achieve, and when the content is more than 30 wt%, formulation is difficult and the feeling in use is reduced.
The quasi-drug composition of the present invention may be preferably in the form of one or more agents selected from the group consisting of body cleansers, disinfecting cleansers, detergents, kitchen cleansers, cleaning cleansers, toothpastes, mouth washes, wet wipes, detergents, soaps, hand sanitizers, hair cleansers, hair softeners, humidifier fillers, masks, ointments, and filter fillers, but is not limited thereto. The same contents as those described in the description of the cosmetic material composition can be applied to the quasi-drug composition of the present invention except for the difference in the dosage form.
From the examples of the present invention, it was confirmed that epipinoresinol inhibits MMP-1 and IL-6 and promotes procollagen production, thereby having anti-aging effect and wrinkle-improving effect. In addition, it was confirmed that epipinoresinol inhibits IL-6, a gene involved in dermatitis, and thus exhibits an anti-inflammatory effect of ameliorating dermatitis.
Hereinafter, preferred embodiments of the present invention will be described to facilitate understanding of the present invention. However, the following examples are provided only for easier understanding of the present invention, and the contents of the present invention are not limited to the following examples.
Examples
Example 1 preparation of samples
Epipophenol used in this example was purchased from Coompo Research Chemicals, and the purchased raw materials were dissolved in DMSO as a solvent at concentrations of 1. mu.g/ml and 10. mu.g/ml, and used in the following experiments.
Example 2 confirmation of collagenase inhibitory Effect of Epicoresinol
The samples were dissolved in DMSO as a solvent at concentrations of 1. mu.g/ml and 10. mu.g/ml, and used in the following experiments.
Specifically, Human fibroblast cell lines (Human dermal fibroplast, Hs68, ATCC) were tested under the following conditions. First, Hs68 fibroblasts were cultured at 2X 104Partition into 96-well plates, then 5% CO at 37 ℃2Incubate for 24 hours in a conditioned incubator. Then, the medium was removed, and after placing DPBS, the medium was used at 15mJ/cm2The remaining cell group except the UVB non-irradiated group was irradiated with UVB, and then epipinoresinol was added at various concentrations and further cultured for 24 hours.
After RNA was isolated from cells of each sample using tricyclazole (RNA iso, DAKARA, Japan), RNA was quantified at 260nm using nanodrop, and cDNA was synthesized in an amplifier using 2. mu.g of each RNA (C1000 Thermal Cycler, Bio-Rad, USA). A mixture of a target protein MMP-1 primer and a cyanine dye SYBR Green (SYBR Green supermix, Applied Biosystems, USA) was added to the synthesized cDNA, and a real-time polymerase chain reaction was performed in a real-time PCR machine, thereby confirming the expression level of the MMP-1 gene. Finally, the expression level of the gene was analyzed by correcting the β -actin (β -actin) gene, and the analysis results are shown in fig. 1.
As shown in FIG. 1, the expression level of MMP-1 gene was significantly reduced in the epipinoresinol-treated group as compared with the increase in the expression level of MMP-1 in the UVB-irradiated group.
It is thus understood that epipinoresinol exhibits wrinkle-improving and anti-aging effects by reducing the expression of MMP-1, which accelerates the formation of wrinkles by decomposing collagen.
TABLE 1
Example 3 confirmation of IL-6 inhibitory Effect of Epicoresinol
To confirm the IL-6 inhibitory effect of epipinoresinol, experiments were performed under the same conditions using the same cells as described in example 1. Except that in the final real-time polymerase chain reaction, an IL-6 primer was used in place of the MMP-1 primer. Finally, the expression level of the gene was analyzed by correcting the β -actin gene, and the analysis results are shown in FIG. 2.
As shown in FIGS. 1 and 2, the IL-6 gene expression level was significantly decreased in the apparent pinoresinol-treated group in a concentration-dependent manner, similarly to the MMP-1 gene expression level.
It is thus understood that epipinoresinol exhibits wrinkle-improving effects and skin irritation-relieving effects by reducing the expression of the inflammatory cytokine IL-6.
TABLE 2
Example 4 confirmation of collagen production promoting Effect of Epicoresinol
To determine the collagen production promoting effect of epipinoresinol in skin cells, experiments were performed using the same cells as those shown in examples 1 and 2 described above.
Under the cell culture conditions of example 1, cells were dispensed into 96-well plates in the same manner, and then 5% CO was dispensed at 37 ℃2The culture was carried out in a conditioned incubator for 24 hours. Then, the medium containing epipinoresinol or TGF-. beta.and the medium containing no potent materials were replaced, and the culture was further carried out for 24 hours. After 24 hours, the medium was collected, and the amount of procollagen secreted into the medium was confirmed using PIP EIA Kit (TAKARA, MK 101). The results are shown in FIG. 3.
Therefore, it was confirmed that epipinoresinol has an effect of improving wrinkles caused by skin aging by promoting collagen synthesis.
Example 5 sensory evaluation of cosmetic Material compositions containing Epipofenol
In order to confirm that the cosmetic material composition containing epipinoresinol has not only an effect of preventing skin aging but also excellent sensory properties when applied to an actual product, the present inventors performed the following sensory evaluation.
Sensory evaluation of anti-aging cosmetic sensory evaluation was performed on 20 women 30 to 50 years old who had experienced experience, and the cream of the following formulation example 3 (example 5, 10) and the cream from which epipinoresinol was removed (comparative example 1, 10) were uniformly applied to the face twice a day for 4 weeks to enable evaluation of the effect. Scores were assigned according to the 5 point scale and averaged.
< evaluation items >
1) Skin aging evaluation based on visual perception and feeling of skin after application
2) Feeling of use
3) Ductility of the alloy
4) Soft feeling
The evaluation criteria are as follows.
< evaluation criteria for sensory evaluation items >
1: very poor, 2: poor, 3: normal, 4: good, 5: very good
TABLE 3
| Distinguishing | Example 5 | Comparative example 1 |
| Aging of skin | 4.3 | 3.5 |
| Feeling of use | 3.7 | 3.6 |
| Ductility of the alloy | 4.1 | 3.8 |
| Soft feeling | 3.5 | 4.0 |
As shown in table 3 above, in the case of example 5 containing epipinoresinol, when used for 4 weeks, superior evaluation was obtained in the skin aging items as compared with comparative example 1. Therefore, the epipinoresinol has excellent sensory properties when applied to actual products.
Formulation example 1 preparation of toner
Skin-refreshing aqueous preparations containing epipinoresinol were prepared by a conventional method according to the composition components and composition ratios shown in table 4 below.
TABLE 4
Formulation example 2 preparation of emulsion
An emulsion containing epipinoresinol was prepared by a conventional method according to the composition components and composition ratios shown in table 5 below.
TABLE 5
Formulation example 3 preparation of cream
A cream containing epipinoresinol was prepared by a conventional method according to the composition components and composition ratios shown in the following table 6.
TABLE 6
The above description of the present invention is illustrative of the present invention, and it will be readily apparent to those skilled in the art that modifications to the present invention may be made without departing from the spirit or essential characteristics thereof. The embodiments described above are therefore exemplary in all respects, and the invention is not limited thereto.
Sequence Listing (sequence list)
<110> coseishi co (COSMAX, INC.)
<120> Cosmetic Composition comprising epipinoresinol (Cosmetic Composition comprising epipinoresinol)
<130> OPC18003-CN
<150> KR 10-2018-0064303
<151> 2018-06-04
<160> 6
<170> KoPatentIn 3.0
<210> 1
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<220>
<223> MMP-1 Forward primer (MMP-1 forward primer)
<400> 1
cgaatttgcc gacagagatg a 21
<210> 2
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<220>
<223> MMP-1 reverse primer (MMP-1 reverse primer)
<400> 2
gtccctgaac agcccagtac tt 22
<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<220>
<223> beta-actin forward primer (beta-actin forward primer)
<400> 3
ggccatctct tgctcgaagt 20
<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<220>
<223> beta-actin reverse primer (beta-actin reverse primer)
<400> 4
gacaccttca acaccccagc 20
<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<220>
<223> IL-6 Forward primer (IL-6 forward primer)
<400> 5
tacccccagg agaagattcc 20
<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<220>
<223> IL-6 reverse primer (IL-6 reverse primer)
<400> 6
ttttctgcca gtgcctcttt 20
Claims (4)
1. A cosmetic composition for preventing skin aging is provided, wherein,
the composition comprises, as an active ingredient, epipinoresinol,
the epipinoresinol inhibits the expression of MMP-1 and IL-6 and promotes the production of type I procollagen.
2. The cosmetic material composition according to claim 1,
the composition improves skin wrinkles.
3. The cosmetic material composition according to claim 1,
the epipinoresinol is present in an amount of 0.001 to 30 wt% relative to the total weight of the composition.
4. The cosmetic material composition according to claim 1,
the composition is in one or more dosage forms selected from the group consisting of a skin toner, an emulsion, and a cream.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2018-0064303 | 2018-06-04 | ||
| KR1020180064303A KR102084415B1 (en) | 2018-06-04 | 2018-06-04 | Cosmetic Composition comprising epipinoresinol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110547975A CN110547975A (en) | 2019-12-10 |
| CN110547975B true CN110547975B (en) | 2022-07-05 |
Family
ID=68735494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910455174.XA Active CN110547975B (en) | 2018-06-04 | 2019-05-29 | Cosmetic material composition containing epipinoresinol |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102084415B1 (en) |
| CN (1) | CN110547975B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1714135A (en) * | 2002-11-22 | 2005-12-28 | 日本水产株式会社 | External composition containing highly unsaturated fatty acid or its salt or ester |
| CN102885726A (en) * | 2011-07-19 | 2013-01-23 | 上海家化联合股份有限公司 | Eucommia extract product, its preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100048322A (en) * | 2008-10-30 | 2010-05-11 | 조홍연 | Protective effects of eucommia ulmoides on uvb-induced oxidative stress in human keratinocytes |
| ES2383271B1 (en) | 2010-03-24 | 2013-08-01 | Lipotec S.A. | PROCESSING PROCESSING OF FIBERS AND / OR TEXTILE MATERIALS |
-
2018
- 2018-06-04 KR KR1020180064303A patent/KR102084415B1/en active IP Right Grant
-
2019
- 2019-05-29 CN CN201910455174.XA patent/CN110547975B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1714135A (en) * | 2002-11-22 | 2005-12-28 | 日本水产株式会社 | External composition containing highly unsaturated fatty acid or its salt or ester |
| CN102885726A (en) * | 2011-07-19 | 2013-01-23 | 上海家化联合股份有限公司 | Eucommia extract product, its preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 天然来源的四氢呋喃型木脂素类化合物生物活性研究进展;孙彦君等;《中成药》;20141031;第36卷(第10期);第2159-2160页 * |
| 杜仲抗皮肤衰老活性成分的筛选及其作用机制研究;张缓;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;中国学术期刊（光盘版）电子杂志社;20170315;第6-7页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190138130A (en) | 2019-12-12 |
| KR102084415B1 (en) | 2020-03-04 |
| CN110547975A (en) | 2019-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101229927B1 (en) | Skin Whitening Composition Using a Litter Extract or a Silk Worm Extract | |
| KR20140012456A (en) | Composition for improving skin conditions comprising akebia saponin d | |
| JP2020502172A (en) | Cosmetic composition containing Chinese herbal extract as active ingredient | |
| CN110547975B (en) | Cosmetic material composition containing epipinoresinol | |
| JPH03112912A (en) | Cosmetic composition | |
| KR20190021114A (en) | Composition for anti-inflammation, inhibiting secretion of sebum, or treating acne on the skin comprising plant extract | |
| KR102014102B1 (en) | Composition for Improving Skin Beauty Comprising Mesquite Honey | |
| JP5155543B2 (en) | Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method | |
| KR20180108254A (en) | Composition for skin improvement containing parishin A | |
| KR20180108255A (en) | Composition for skin improvement containing parishin B | |
| KR101117561B1 (en) | Cosmetic Composition for Anit-Aging Comprising Flavonoid as Active Ingredients | |
| JP7485336B2 (en) | MSX-2 mRNA expression promoter, eyelash growth agent, and external preparation composition for eyelash growth | |
| KR20120076168A (en) | Skin antiaging agent and composition for skin antiaging comprising the same | |
| KR20110101727A (en) | Composition for improving skin wrinkle | |
| KR20100001167A (en) | Cosmetic composition comprising quercitrin and/or myricitrin as active ingredients | |
| KR20180061663A (en) | Composition for skin improvement containing dehydroevodiamine | |
| KR20190020361A (en) | A cosmetic composition and a pharmaceutic composition for preventing skin aging or improving skin wrinkles containing heparinoid | |
| KR100515951B1 (en) | Cosmetic Composition Comprising Sophorae Flos Extract and Arbutin for Skin Whitening | |
| KR20230067034A (en) | Method for producing lactoferrin derivative having functions such as antioxidant, whitening, anti-inflammatory and skin protection, and skin treatment ointment and cosmetic composition comprising the same | |
| KR20160067428A (en) | COMPOSITION FOR MOISTURIZING THE SKIN CONTAINING (2S)-1-O-LINOLENOYL-2-O-LINOLENOYL-3-O-β-D-GALACTOPYRANOSYL-SN-GLYCEROL | |
| KR20200036730A (en) | A composition for promoting skin turnover and promoting melanin release | |
| KR20200110895A (en) | Composition for improving skin wrinkle or elasticity comprising rhaponticin | |
| KR20160066186A (en) | Composition for moisturizing the skin containing picrionoside A | |
| KR20100036644A (en) | Cosmetic composition comprising corilagin as active ingredients | |
| KR101434446B1 (en) | Composition for External Application to the Skin Using an Extract of Dictyota dichotoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |